Future Fields

About Future Fields

Future Fields utilizes its EntoEngine™ platform to produce custom recombinant proteins using fruit flies, enabling the scalable manufacturing of difficult-to-express proteins. This approach addresses the challenges of high production costs and environmental impact associated with traditional protein synthesis methods.

```xml <problem> Traditional methods of recombinant protein production often face challenges related to scalability, high costs, and environmental concerns, particularly when dealing with difficult-to-express proteins. These limitations can hinder research and development efforts across various industries. </problem> <solution> Future Fields offers the EntoEngine™ platform, a novel biomanufacturing approach that leverages fruit flies for the production of custom recombinant proteins. This technology enables the scalable and cost-effective manufacturing of proteins that are traditionally difficult to express using conventional methods. By utilizing fruit flies as bioreactors, Future Fields provides a sustainable alternative to traditional protein synthesis, reducing both production costs and environmental impact. The platform aims to make previously unmakeable proteins accessible for a variety of applications. </solution> <features> - EntoEngine™ platform utilizing fruit flies as bioreactors for protein production - Scalable manufacturing of difficult-to-express recombinant proteins - Sustainable and cost-effective alternative to traditional protein synthesis methods - Custom protein production services tailored to specific research and development needs </features> <target_audience> The primary target audience includes researchers, biotech companies, and other organizations requiring access to high-quality, difficult-to-express recombinant proteins for various applications. </target_audience> ```

What does Future Fields do?

Future Fields utilizes its EntoEngine™ platform to produce custom recombinant proteins using fruit flies, enabling the scalable manufacturing of difficult-to-express proteins. This approach addresses the challenges of high production costs and environmental impact associated with traditional protein synthesis methods.

Where is Future Fields located?

Future Fields is based in Edmonton, Canada.

When was Future Fields founded?

Future Fields was founded in 2018.

How much funding has Future Fields raised?

Future Fields has raised 14400000.

Location
Edmonton, Canada
Founded
2018
Funding
14400000
Employees
44 employees
Major Investors
Bee Partners, Toyota Ventures

Find Investable Startups and Competitors

Search thousands of startups using natural language

Future Fields

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

Future Fields utilizes its EntoEngine™ platform to produce custom recombinant proteins using fruit flies, enabling the scalable manufacturing of difficult-to-express proteins. This approach addresses the challenges of high production costs and environmental impact associated with traditional protein synthesis methods.

futurefields.io5K+
cb
Crunchbase
Founded 2018Edmonton, Canada

Funding

$

Estimated Funding

$10M+

Major Investors

Bee Partners, Toyota Ventures

Team (40+)

No team information available.

Company Description

Problem

Traditional methods of recombinant protein production often face challenges related to scalability, high costs, and environmental concerns, particularly when dealing with difficult-to-express proteins. These limitations can hinder research and development efforts across various industries.

Solution

Future Fields offers the EntoEngine™ platform, a novel biomanufacturing approach that leverages fruit flies for the production of custom recombinant proteins. This technology enables the scalable and cost-effective manufacturing of proteins that are traditionally difficult to express using conventional methods. By utilizing fruit flies as bioreactors, Future Fields provides a sustainable alternative to traditional protein synthesis, reducing both production costs and environmental impact. The platform aims to make previously unmakeable proteins accessible for a variety of applications.

Features

EntoEngine™ platform utilizing fruit flies as bioreactors for protein production

Scalable manufacturing of difficult-to-express recombinant proteins

Sustainable and cost-effective alternative to traditional protein synthesis methods

Custom protein production services tailored to specific research and development needs

Target Audience

The primary target audience includes researchers, biotech companies, and other organizations requiring access to high-quality, difficult-to-express recombinant proteins for various applications.

Want to add first party data to your startup here or get your entry removed? You can edit it yourself by logging in with your company domain.